Who Owns Fagron Company?

Who Owns Fagron?

Understanding Fagron's ownership is key to grasping its strategic path and influence in pharmaceutical compounding. A major shift occurred with its IPO on October 5, 2007, marking a new era for its ownership structure.

Fagron's journey began in Rotterdam in 1990, initially distributing medicinal raw materials. After an acquisition and subsequent spin-off, it evolved into the global pharmaceutical compounding leader it is today, active in over 30 countries with more than 4,000 employees.

As of July 18, 2025, Fagron's market capitalization stood at approximately $1.87 billion, with 72.9 million shares outstanding. This analysis explores Fagron's ownership journey, from its early investors to its current institutional shareholders and board makeup, including insights into its Fagron PESTEL Analysis.

Fagron's journey began in 1990 when Ger van Jeveren established the company in Rotterdam, Netherlands. Initially, its operations centered on distributing raw materials crucial for pharmaceutical compounding. The early ownership structure saw a significant transition in 2000 when Omega Pharma acquired Fagron, integrating it into their professional healthcare division.

Founding Vision

Ger van Jeveren founded Fagron with a clear focus on supplying essential raw materials for pharmaceutical compounding. His entrepreneurial spirit laid the groundwork for the company's future growth in this specialized market.

Omega Pharma Integration

The acquisition by Omega Pharma in 2000 marked a pivotal moment, bringing Fagron under a larger corporate umbrella. This integration aimed to leverage synergies within Omega Pharma's professional healthcare services.

Emergence of Arseus NV

In 2006, Arseus NV was created to consolidate various smaller companies, including Fagron, from Omega Pharma's B2B healthcare operations. This move signaled a strategic restructuring and preparation for independent operations.

Path to Independence

The company's initial public offering in October 2007 was a landmark event, solidifying its status as an independent entity. This public listing provided access to capital markets and enhanced its visibility.

Founding Ownership Details

While specific equity details for Ger van Jeveren at the company's inception are not publicly disclosed, his role as founder was crucial. His vision and early leadership were instrumental in shaping Fagron's initial direction.

Public Listing Significance

The listing on Euronext Brussels and Euronext Amsterdam in 2007 was a key step in Fagron's corporate evolution. It allowed for broader ownership and increased transparency in its financial dealings.

The initial ownership structure of Fagron was closely tied to its founder, Ger van Jeveren. Following its acquisition by Omega Pharma in 2000, Fagron became part of a larger entity. The subsequent formation of Arseus NV in 2006 as an umbrella organization for Omega Pharma's B2B healthcare segment, including Fagron, set the stage for its eventual independence. This independence was formally achieved through an IPO in October 2007, making Fagron a publicly traded company and shifting its ownership landscape significantly. Understanding this early history is key to grasping the current Fagron ownership. For a deeper dive into the competitive environment, explore the Competitors Landscape of Fagron.

Key Ownership Milestones

Fagron's ownership has evolved through several critical stages, from its founding to becoming a publicly traded entity.

• Founding in 1990 by Ger van Jeveren.
• Acquisition by Omega Pharma in 2000.
• Integration into Arseus NV in 2006.
• Initial Public Offering (IPO) in October 2007, leading to public ownership.

Fagron NV transitioned to a publicly traded entity on October 5, 2007, initially as Arseus NV, on Euronext exchanges. This IPO marked a significant shift in its ownership structure, moving from a private to a publicly accessible company. The company's journey since then has seen various capital increases and market activities that have reshaped its shareholder base.

The ownership landscape of Fagron NV is predominantly shaped by institutional investors, who collectively hold a substantial 74% stake as of July 2025. This significant institutional backing underscores the company's appeal to larger investment entities. The total number of Fagron shares with voting rights was 73,313,904 as of June 6, 2025. Key major shareholders include The Goldman Sachs Group, Inc. with 18%, NN Group N.V., Asset Management Arm holding 16%, and AOC Pharma S.à r.l. with 11%. FMR LLC, also known as Fidelity Management & Research Company LLC, increased its holding to 4.51% as of November 18, 2024, surpassing the 3% disclosure threshold. Other notable investors like Mawer Investment Management Ltd. and Alychlo NV have also been active participants in Fagron's shareholder structure, with Alychlo NV filing a downward crossing notification on July 25, 2024. Fagron's history includes capital increases, such as the one in 2016 involving entities like WPEF VI Holdco III BE B.V. and Alychlo NV, and more recently, the issuance of 85,000 new shares on June 6, 2025, due to the exercise of subscription rights, all of which have contributed to the dynamic nature of its Fagron ownership. Understanding who owns Fagron provides insight into its strategic direction and market positioning.

Key Fagron Shareholders

Fagron's shareholder base is dominated by institutional investors, reflecting broad market confidence. Several major entities hold significant stakes, influencing the company's trajectory.

• Institutional investors collectively own 74% of Fagron NV.
• The Goldman Sachs Group, Inc. is a major stakeholder with 18%.
• NN Group N.V., Asset Management Arm holds 16% of the company's shares.
• AOC Pharma S.à r.l. possesses 11% of the outstanding shares.
• FMR LLC increased its stake to 4.51% in late 2024.

As of May 8, 2023, Fagron's Board of Directors is led by Koen Hoffman as the independent non-executive Chair. The board includes executive members Rafael Padilla (CEO) and Karin de Jong (CFO), alongside independent non-executive directors Neeraj Sharma, Klaus Röhrig, Els Vandecandelaere, Rob ten Hoedt, and Ann Desender.

While board members and the executive team hold shares, their combined ownership represents less than 1% of Fagron NV, valued at approximately €2.6 million as of July 2025. The company operates on a one-share-one-vote principle, with 73,313,904 shares carrying voting rights. Transparency regarding major shareholdings is maintained through notifications required upon crossing thresholds of 3%, 5%, and subsequent multiples of 5%, as stipulated in Article 11 of the company's articles of association. The company has experienced stable governance, with all voting items approved at the May 12, 2025, annual general meeting, including the 2024 financial statements, a dividend of €0.35 per share, and the remuneration policy. Understanding the Marketing Strategy of Fagron can provide further insight into the company's operations and how it engages its stakeholders.

Fagron's Governance and Voting Structure

Fagron's voting power is distributed based on a one-share-one-vote system, ensuring that each share held corresponds to a single vote. Major shareholders are required to disclose their stakes to maintain transparency in Fagron company ownership.

• Total voting shares: 73,313,904
• Shareholding notification thresholds: 3%, 5%, and multiples thereof
• Executive and board ownership: Less than 1% of total shares
• Recent AGM approvals: 2024 financial statements, dividend, and remuneration policy

Recent developments in Fagron's ownership structure reflect strategic capital management and market expansion. The company's share buy-back program and capital increases in 2024 and 2025 have adjusted its outstanding share count, while acquisitions signal a focus on strengthening its market position.

Institutional investors hold a significant portion of Fagron's stock, indicating substantial confidence from the financial community. As of July 2025, institutions own approximately 74% of Fagron NV. A notable shift in this backing occurred in November 2024 when FMR LLC (Fidelity) increased its stake to 4.51%. Fagron's leadership has presented an ambitious growth strategy, targeting an REBITDA margin of around 21.0% by 2027, with mergers and acquisitions expected to be a key driver of value creation. The company anticipates continued organic revenue growth and improved profitability throughout 2025.

Institutional Investor Confidence

Institutions held about 74% of Fagron NV as of July 2025. FMR LLC notably raised its stake to 4.51% in November 2024.

Strategic Growth Initiatives

The company aims for a 21.0% REBITDA margin by 2027. Mergers and acquisitions are seen as crucial for value creation.

Capital Structure Adjustments

A share buy-back program in late 2024 reduced outstanding shares. A capital increase in June 2025 further adjusted the share count.

Market Expansion Through M&A

The acquisition of Guinama in February 2025 is a key step in strengthening Fagron's market position and expanding its reach.